{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:48:57Z","timestamp":1792691337411,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK072482"],"award-info":[{"award-number":["P30DK072482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jcf.2023.04.008","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:57:16Z","timestamp":1682729836000},"page":"656-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":168,"title":["Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double\u2010blind, placebo\u2010controlled phase 1\/2 clinical study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-0133","authenticated-orcid":false,"given":"S.M.","family":"Rowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8190-9210","authenticated-orcid":false,"given":"J.B.","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3996-9535","authenticated-orcid":false,"given":"D.","family":"Dorgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lascano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-0905","authenticated-orcid":false,"given":"K.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1534-5629","authenticated-orcid":false,"given":"M.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-3767","authenticated-orcid":false,"given":"M.S.","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9675-957X","authenticated-orcid":false,"given":"V.","family":"Indihar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lechtzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"McBennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Callison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-0561","authenticated-orcid":false,"given":"C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.G.","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.D.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Z.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0144-7897","authenticated-orcid":false,"given":"S.","family":"Bodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.B.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2023.04.008_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.04.008_bib0002","series-title":"Cystic fibrosis foundation patient registry - 2021 Annual data report","year":"2022"},{"issue":"6","key":"10.1016\/j.jcf.2023.04.008_bib0003","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2023.04.008_bib0004","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.04.008_bib0005","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"4","key":"10.1016\/j.jcf.2023.04.008_bib0006","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"136","author":"Houseley","year":"2009","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.jcf.2023.04.008_bib0007","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1096\/fasebj.3.12.2676679","article-title":"The role of mRNA and protein stability in gene expression","volume":"3","author":"Hargrove","year":"1989","journal-title":"Faseb j"},{"issue":"20","key":"10.1016\/j.jcf.2023.04.008_bib0008","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jcf.2023.04.008_bib0009","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.008_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J Transl Med"},{"issue":"12","key":"10.1016\/j.jcf.2023.04.008_bib0011","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.008_bib0012","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/nat.2017.0697","article-title":"Leveraging Rational Protein Engineering to Improve mRNA Therapeutics","volume":"28","author":"Farelli","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.008_bib0013","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.008_bib0014","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2017.12.024","article-title":"Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency","volume":"26","author":"Prieve","year":"2018","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.jcf.2023.04.008_bib0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ymthe.2018.01.006","article-title":"G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a","volume":"26","author":"Roseman","year":"2018","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.jcf.2023.04.008_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of fabry disease: preclinical studies in wild-type mice, fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"S2","key":"10.1016\/j.jcf.2023.04.008_bib0017","first-page":"253","article-title":"In vitro and in vivo evaluation of an mRNA therapeutic for the treatment of patients with cystic fibrosis","volume":"53","author":"Barbier","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.04.008_bib0018","first-page":"A515","article-title":"Safety and tolerability of a single dose of MRT5005, an inhaled CFTR mRNA therapeutic, in adult CF patients","volume":"54","author":"Zuckerman","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.04.008_bib0019","doi-asserted-by":"crossref","first-page":"s257","DOI":"10.1016\/S1569-1993(21)01967-6","article-title":"Safety and tolerability of single and repeated doses of MRT5005, an inhaled CFTR mRNA replacement therapy, in adult CF patients","volume":"20","author":"Rowe","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.04.008_bib0020","series-title":"Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR. patent application publication","first-page":"1","author":"Barbier","year":"2022"},{"issue":"2","key":"10.1016\/j.jcf.2023.04.008_bib0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jcf.2023.04.008_bib0022","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"9157","key":"10.1016\/j.jcf.2023.04.008_bib0023","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(98)06532-5","article-title":"Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial","volume":"353","author":"Alton","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.04.008_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/JAA.S159411","article-title":"Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers","volume":"11","author":"Jimenez-Rodriguez","year":"2018","journal-title":"J Asthma Allergy"},{"issue":"5","key":"10.1016\/j.jcf.2023.04.008_bib0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.04.008_bib0026","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5663","key":"10.1016\/j.jcf.2023.04.008_bib0027","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jcf.2023.04.008_bib0028","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.rmed.2010.12.001","article-title":"Exogenous lipoid pneumonia. Clinical and radiological manifestations","volume":"105","author":"Marchiori","year":"2011","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.04.008_bib0029","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0272-5231(21)00680-8","article-title":"Drug-induced bronchospasm","volume":"11","author":"Meeker","year":"1990","journal-title":"Clin Chest Med"},{"issue":"6","key":"10.1016\/j.jcf.2023.04.008_bib0030","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1164\/ajrccm\/141.6.1405","article-title":"Effect of inhaled preservatives on asthmatic subjects. II. Benzalkonium chloride","volume":"141","author":"Zhang","year":"1990","journal-title":"Am Rev Respir Dis"},{"issue":"11","key":"10.1016\/j.jcf.2023.04.008_bib0031","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat Biotechnol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:33:39Z","timestamp":1751567619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1569199323001121"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double\u2010blind, placebo\u2010controlled phase 1\/2 clinical study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}